z-logo
Premium
Clinically targeted screening for congenital CMV – potential for integration into the National Hearing Screening Programme
Author(s) -
Kadambari S,
Luck S,
Davis A,
Williams EJ,
Berrington J,
Griffiths PD,
Sharland M
Publication year - 2013
Publication title -
acta paediatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/apa.12335
Subject(s) - medicine , pediatrics , sensorineural hearing loss , hearing loss , ganciclovir , intensive care medicine , cytomegalovirus , audiology , viral disease , family medicine , immunology , herpesviridae , virus , human cytomegalovirus , human immunodeficiency virus (hiv)
Screening for a condition should only be undertaken if certain strict criteria are met. Congenital CMV (c CMV ) is a leading cause of sensorineuronal hearing loss ( SNHL ) and meets many of these criteria, but is not currently screened for in the UK . Ganciclovir reduces CMV ‐induced progressive SNHL if treatment is begun in the first month of life. The Newborn Hearing Screening Programme ( NHSP ) has been shown to identify SNHL at the earliest possible age. The potential of integrating screening for c CMV into the NHSP is discussed to consolidate the link between screening, early diagnosis and management. Conclusion The early diagnosis and treatment of c CMV may prevent a small proportion of late SNHL . In the absence of any screening programme, we provide evidence that clinically targeted screening through the NHSP is a potential option in the UK , enhancing the diagnostic pathway and enabling appropriate early treatment to reduce long‐term morbidity.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here